Healthcare & Life Sciences
Coultreon Biopharma
Belgium
series-a
series-a
Stage
1
Investors
About
Coultreon Biopharma develops oral drugs targeting the SIK3 pathway to modulate the immune system and reduce pro-inflammatory cytokine production for treating chronic inflammatory diseases with high unmet medical needs.
Explore Coultreon Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.